Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes
- 8 October 2017
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (2) , 468-473
Abstract
A retrospective cohort study was conducted in patients with type 2 diabetes in an electronic medical record database to compare real‐world, 6‐month glycated haemoglobin (HbA1c) and weight outcomes for exenatide once weekly with those for dulaglutide and albiglutide. The study included 2465 patients: exenatide once weekly, n = 2133; dulaglutide, n = 201; and albiglutide, n = 131. The overall mean (standard deviation [s.d.]) age was 60 (11) years and 54% were men; neither differed among the comparison groups. The mean (s.d.) baseline HbA1c was similar in the exenatide once‐weekly (8.3 [1.7]%) and dulaglutide groups (8.5 [1.5]%; P = .165), but higher in the albiglutide group (8.7 [1.7]%; P < .001). The overall mean (s.d.) HbA1c change was −0.5 (1.5)% ( P < .001) and this did not differ among the comparison groups in either adjusted or unadjusted analyses. The mean (s.d.) weight change was −1.4 (4.7) kg for exenatide once weekly and −1.6 (3.7) kg for albiglutide ( P = .579), but was greater for dulaglutide, at −2.7 (5.7) kg ( P = .001). Outcomes were similar in subsets of insulin‐naive patients with baseline HbA1c ≥7.0% or ≥9.0%. All agents significantly reduced HbA1c at 6 months, with no significant differences among agents or according to baseline HbA1c in insulin‐naive subgroups.Keywords
Funding Information
- AstraZeneca
This publication has 17 references indexed in Scilit:
- Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort AnalysisClinical Therapeutics, 2016
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trialThe Lancet Diabetes & Endocrinology, 2016
- A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondDrugs in Context, 2015
- GLP-1 receptor agonists: a review of head-to-head clinical studiesTherapeutic Advances in Endocrinology and Metabolism, 2014
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialThe Lancet, 2014
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 studyThe Lancet Diabetes & Endocrinology, 2014
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyThe Lancet, 2013
- The Effect of Physical Activity on 18‐Month Weight Change in Overweight AdultsObesity, 2011
- The definition of weight maintenanceInternational Journal of Obesity, 2005
- IFCC Reference System for Measurement of Hemoglobin A1c in Human Blood and the National Standardization Schemes in the United States, Japan, and Sweden: A Method-Comparison StudyClinical Chemistry, 2004